Sustained-Release Naltrexone For Opioid Dependence

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

“…Psychiatrists may not have the staff and office resources to provide injections. While oral naltrexone may be a good option for highly motivated patients (Lobmaier, Kornør, Kunøe, & Bjørndal, 2008), a systematic review failed to find enough evidence to recommend oral naltrexone, acknowledging that its effectiveness was limited by poor adherence (Minozzi et al, 2011). Further oral naltrexone may pose an elevated risk of overdose after discontinuation because oral naltrexone is cleared after only 24 hours, leaving patients with low opioid tolerance.…”

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

“…Psychiatrists may not have the staff and office resources to provide injections. While oral naltrexone may be a good option for highly motivated patients (Lobmaier, Kornør, Kunøe, & Bjørndal, 2008), a systematic review failed to find enough evidence to recommend oral naltrexone, acknowledging that its effectiveness was limited by poor adherence (Minozzi et al, 2011). Further oral naltrexone may pose an elevated risk of overdose after discontinuation because oral naltrexone is cleared after only 24 hours, leaving patients with low opioid tolerance.…”

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)

“…This study has the potential to become the first comparison between extended-release naltrexone and daily buprenorphine-naloxone for opioid dependence. Such comparisons are currently lacking from the knowledge base [ 47 ]. In addition, longer-term data on the performance of XR-NTX in opioid dependent patients is central in evaluating the clinical feasibility of XR-NTX in this high-risk, chronically relapsing patient group.…”

Long-acting Preparations in Substance Abuse Management: A Review and Update

“…In 2008, Lobmaier, et al . [66] conducted a Cochrane meta-analysis of naltrexone sustained release preparations (included depot injections and implants). After analysis, the authors could comment that depot injections seemed promising, though the overall data was insufficient.…”

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

“…Psychiatrists may not have the staff and office resources to provide injections. While oral naltrexone may be a good option for highly motivated patients (Lobmaier, Kornør, Kunøe, & Bjørndal, 2008), a systematic review failed to find enough evidence to recommend oral naltrexone, acknowledging that its effectiveness was limited by poor adherence (Minozzi et al, 2011). Further oral naltrexone may pose an elevated risk of overdose after discontinuation because oral naltrexone is cleared after only 24 hours, leaving patients with low opioid tolerance.…”

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)

“…This study has the potential to become the first comparison between extended-release naltrexone and daily buprenorphine-naloxone for opioid dependence. Such comparisons are currently lacking from the knowledge base [ 47 ]. In addition, longer-term data on the performance of XR-NTX in opioid dependent patients is central in evaluating the clinical feasibility of XR-NTX in this high-risk, chronically relapsing patient group.…”

Long-acting Preparations in Substance Abuse Management: A Review and Update

“…In 2008, Lobmaier, et al . [66] conducted a Cochrane meta-analysis of naltrexone sustained release preparations (included depot injections and implants). After analysis, the authors could comment that depot injections seemed promising, though the overall data was insufficient.…”

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

“…Psychiatrists may not have the staff and office resources to provide injections. While oral naltrexone may be a good option for highly motivated patients (Lobmaier, Kornør, Kunøe, & Bjørndal, 2008), a systematic review failed to find enough evidence to recommend oral naltrexone, acknowledging that its effectiveness was limited by poor adherence (Minozzi et al, 2011). Further oral naltrexone may pose an elevated risk of overdose after discontinuation because oral naltrexone is cleared after only 24 hours, leaving patients with low opioid tolerance.…”

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)

“…This study has the potential to become the first comparison between extended-release naltrexone and daily buprenorphine-naloxone for opioid dependence. Such comparisons are currently lacking from the knowledge base [ 47 ]. In addition, longer-term data on the performance of XR-NTX in opioid dependent patients is central in evaluating the clinical feasibility of XR-NTX in this high-risk, chronically relapsing patient group.…”

Long-acting Preparations in Substance Abuse Management: A Review and Update

“…In 2008, Lobmaier, et al . [66] conducted a Cochrane meta-analysis of naltrexone sustained release preparations (included depot injections and implants). After analysis, the authors could comment that depot injections seemed promising, though the overall data was insufficient.…”